CagriSema 10mg (ngwakọta)

▎ Gịnị bụ Semaglutid?

Semaglutid, dị ka glucagon-dị ka peptide-1 (GLP-1) agonist receptor agonist, ejirila ya mee ihe n'ọtụtụ ebe na ọgwụgwọ ụlọ ọgwụ nke ụdị ọrịa shuga mellitus 2. Site na iṅomi ọrụ physiological nke GLP-1 eke, ọgwụ a na-akpalite ọtụtụ usoro nhazi usoro metabolic mgbe ọ gbasịrị GLP-1 nnabata, gụnyere nkwalite nke insulin na-adabere na glucose, usoro mgbochi nke mwepụta glucagon, igbu oge nke mkpofu gastric, yana mmetụta nkwụsị nke agụụ nke etiti, si otú ahụ na-enweta ọkwa nchịkwa nke glucose ọbara. Ngwongwo pharmacokinetic ya pụrụ iche na-enye ya ọkara ndụ ihe ruru ụbọchị 7, na-akwado usoro ịgba ọgwụ mgbochi subcutaneous otu ugboro kwa izu ma ọ bụ usoro nchịkwa ọnụ kwa ụbọchị, nke na-ebuli ahụmịhe ọgwụgwọ nke ndị ọrịa nke ukwuu ma na-emezi nnabata ọgwụ.

Nnwale nnwale ụlọ ọgwụ na-egosi na semaglutide nwere ike belata ọkwa haemoglobin glycated (HbA1c) nke ukwuu ruo 1.8%, yana ihe omume hypoglycemic dị ntakịrị, nke na-enye ya ohere pụrụ iche na njikwa glucose ọbara. Tụkwasị na nke ahụ, a kwadoro mmetụta nchebe obi nke ọgwụ a n'ụzọ zuru ezu, nke nwere ike ibelata ihe ize ndụ nke nnukwu ọrịa obi na-adịghị mma site na 26%, na-enye ndị ọzọ uru ọgwụgwọ ọgwụgwọ maka ndị ọrịa mamịrị nwere ọrịa obi. Na mgbakwunye na ọgwụgwọ ọrịa shuga, enwere ike iji semaglutide maka njikwa ogologo oge nke oke ibu ma gosipụta uru ọgwụgwọ nwere ike na nyocha ụlọ ọgwụ gbasara ọrịa dịka steatohepatitis na-abụghị mmanya na ọrịa Alzheimer.

Usoro ọgwụgwọ ọtụtụ ebumnuche dabere na ịgbalite nnabata GLP-1 ọ bụghị naanị na-eme ka usoro metabolic dịkwuo elu site na imeziwanye uche insulin, na-egbochi oke glucagon, yana ịhazi etiti nguzozi ike nke etiti, kamakwa na-enye usoro ọgwụgwọ ọhụụ maka njikwa zuru oke nke ọrịa metabolic na-adịghị ala ala site na mmetụta nchebe obi na uru nke sistemu ụjọ. Enwere ike itinye ya n'ọtụtụ mpaghara ọrịa na-akwadokwa ọnọdụ dị mkpa nke GLP-1 agonists na-anabata ya dị ka usoro ọgwụgwọ bụ isi na ọgwụ metabolic ọgbara ọhụrụ.

▎ Nchịkọta

Nchikota nke Cagrilintide na Semaglutid (Cagrisema) na-egosi mmetụta synergistic dị ịrịba ama na ọgwụgwọ oke ibu na ụdị ọrịa shuga 2. Usoro ọgwụgwọ ngwakọta a na-enweta ọtụtụ usoro nke agụụ, glucose metabolism na njikwa ibu site n'otu oge na-ezubere ndị na-anabata amylin na GLP-1. Cagrilintide na-achịkwa site na mkpochapụ afọ na-egbu oge yana ụkpụrụ satiety etiti, ebe Semaglutid na-egbochi secretion glucagon ma na-akwalite mmepụta insulin. The synergistic mmetụta nke abụọ budata enhances mmetụta nke arọ ọnwụ na ọbara ịchịkwa glucose.

Data nyocha nke ụlọ ọgwụ na-egosi na Cagrisema (nchikota nke Cagrilintide 2.4mg na Semaglutid 2.4mg) na-eduga ná nkwụsịtụ dị arọ nke 9.07% (nkwụsị zuru oke nke 9.11kg) n'oge ọgwụgwọ nke 20 ruo 32 izu, nke dị mma karịa usoro ọgwụgwọ nke iji Semaglutid naanị otu ^izu . N'ime izu 32, multicenter, onye kpuru ìsì abụọ, usoro 2 na-ahụ maka ụlọ ọgwụ, ọnwụ dị arọ nke ndị ọrịa na-agwọ ọrịa CagriSema dị nnọọ ukwuu karịa nke ndị ọrịa na-emeso Semaglutid ma ọ bụ Cagrilintide naanị. 

Mbelata dị arọ na otu CagriSema bụ -15.6%, na n'ime otu Semaglutid bụ -5.1%, na na Cagrilintide bụ -8.1% ^[2] . Na mgbakwunye, Cagrisema na-arụkwa ọrụ nke ọma n'ibelata haemoglobin glycated (HbA1c) na imeziwanye ihe ngosi ihe egwu nke obi, ebe ihe ize ndụ nke hypoglycemia dị obere. Site na usoro ebumnuche ọtụtụ, usoro ọgwụgwọ ngwakọta a abụghị naanị na-ebuli paramita metabolic, kamakwa na-ebelata ihe egwu nke ọrịa obi, na-enye nhọrọ ọgwụgwọ zuru oke maka ndị ọrịa nwere oke ibu na ụdị ọrịa shuga 2.

Banyere Onye dere ya

Ihe niile a kpọtụrụ aha n'elu bụ Cocer Peptides na-enyocha, dezie ma chịkọta ya.

▎ Okwu ndị dị mkpa

[1] Dutta D, Nagendra L, Harish BG, et al. Ịrụ Ọrụ na Nchekwa nke Cagrilintide Nanị yana na Nchikota na Semaglutid (Cagrisema) dị ka ọgwụ mgbochi oke ibu: Nyocha usoro na Meta-Analysis[J]. Akwụkwọ akụkọ India nke Endocrinology na Metabolism, 2024,28:436-444.DOI:10.4103/ijem.ijem_45_24.

[2] Frias JP, Deenadayalan S, Erichsen L, et al. Ịdị irè na nchekwa nke cagrilintide otu ugboro kwa izu 2 · 4 mg na semaglutide otu ugboro kwa izu 2 · 4 mg na ụdị ọrịa shuga 2: multicentre, randomized, double-kpuru, na-arụ ọrụ na-achịkwa, usoro 2 ikpe [J]. Lancet, 2023,402 (10403):720-730.DOI:10.1016/S0140-6736(23)01163-7.

Akụkọ niile na ozi ngwaahịa enyere na webụsaịtị a bụ naanị maka mgbasa ozi na ebumnuche mmụta.  

Ngwaahịa ndị enyere na webụsaịtị a bụ naanị maka nyocha in vitro. A na-eme nyocha in vitro (Latin: * na iko *, nke pụtara na ihe eji enyo) na mpụga ahụ mmadụ. Ngwaahịa ndị a abụghị ọgwụ, ndị US Food and Drug Administration (FDA) akwadoghị ya, ha agaghịkwa eji ya gbochie, gwọọ, ma ọ bụ gwọọ ọnọdụ ahụike ọ bụla, ọrịa, ma ọ bụ ọrịa. Iwu amachibidoro nke ọma iwebata ngwaahịa ndị a n'ime ahụ mmadụ ma ọ bụ anụmanụ n'ụdị ọ bụla.